Key Takeaways
- • Clayton, Dubilier & Rice appoints Giovanni Caforio, former Bristol-Myers Squibb CEO and current Novartis chairman, as an operating adviser to source and assess European healthcare investment opportunities.
- • Caforio brings over two decades of pharmaceutical industry experience, including 15+ years at Bristol-Myers Squibb where he served as CEO and chairman before joining Novartis last year.
- • CD&R has executed a targeted healthcare hiring strategy in 2026, recruiting three senior operating advisers (Caforio, Matthew Trerotola in June, and John Chiminski in July) to strengthen deal sourcing and portfolio company performance.
- • The move reflects CD&R's strategy to maintain focus on traditional private equity buyouts while expanding its healthcare pipeline, contrasting with competitors who have diversified into private credit and infrastructure.
- • CD&R closed its latest flagship buyout fund at $26 billion in 2023 and is currently raising a new flagship vehicle, with recent large-scale healthcare transactions including a controlling stake in French pharmaceutical group Sanofi.
Summary
Clayton, Dubilier & Rice has strengthened its healthcare investment capabilities by appointing Giovanni Caforio, the former chief executive of Bristol-Myers Squibb, as an operating adviser. Caforio, who currently serves as chairman of Swiss pharmaceutical company Novartis, will collaborate with CD&R's investment team to identify and evaluate healthcare opportunities across Europe while supporting portfolio company operations.
Caforio's 22-year tenure at Bristol-Myers Squibb establishes significant credibility for this role. He joined the pharmaceutical company from Abbott Laboratories in 2000 and ascended to the CEO position in 2015, later serving as chairman before transitioning to Novartis last year. His dual expertise in large-cap pharma operations and regulatory navigation positions him to advise on the complex deals characteristic of European healthcare markets.
The appointment represents part of a deliberate institutional strategy by CD&R to embed former C-suite executives within its investment operations. This approach leverages sector expertise, regulatory knowledge, and industry relationships to enhance deal sourcing and improve operating performance at portfolio companies. The firm has accelerated this strategy in 2026, recruiting three senior healthcare advisers: Trerotola, former CEO of Enovis, joined in June to cover healthcare and industrial investments, followed by John Chiminski, former Catalent chairman and CEO, in July.
CD&R's recruitment focus underscores its commitment to maintaining traditional private equity buyouts as its core business model. Unlike major competitors that have expanded into private credit and infrastructure, CD&R is concentrating on deepening its healthcare pipeline. The firm closed its latest flagship buyout fund at $26 billion in 2023 and is currently fundraising for a new flagship vehicle. Recent transactions demonstrate this healthcare focus, including CD&R's acquisition of a controlling stake in French pharmaceutical group Sanofi, reflecting the firm's appetite for large-scale healthcare transactions in European markets.
Caforio's 22-year tenure at Bristol-Myers Squibb establishes significant credibility for this role. He joined the pharmaceutical company from Abbott Laboratories in 2000 and ascended to the CEO position in 2015, later serving as chairman before transitioning to Novartis last year. His dual expertise in large-cap pharma operations and regulatory navigation positions him to advise on the complex deals characteristic of European healthcare markets.
The appointment represents part of a deliberate institutional strategy by CD&R to embed former C-suite executives within its investment operations. This approach leverages sector expertise, regulatory knowledge, and industry relationships to enhance deal sourcing and improve operating performance at portfolio companies. The firm has accelerated this strategy in 2026, recruiting three senior healthcare advisers: Trerotola, former CEO of Enovis, joined in June to cover healthcare and industrial investments, followed by John Chiminski, former Catalent chairman and CEO, in July.
CD&R's recruitment focus underscores its commitment to maintaining traditional private equity buyouts as its core business model. Unlike major competitors that have expanded into private credit and infrastructure, CD&R is concentrating on deepening its healthcare pipeline. The firm closed its latest flagship buyout fund at $26 billion in 2023 and is currently fundraising for a new flagship vehicle. Recent transactions demonstrate this healthcare focus, including CD&R's acquisition of a controlling stake in French pharmaceutical group Sanofi, reflecting the firm's appetite for large-scale healthcare transactions in European markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.